Gout relief: should you take meds immediately?
NCT ID NCT05109936
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether giving gout medication (febuxostat) right after an attack is better than waiting 6 weeks, which is the current standard. About 128 people with gout will be split into two groups to compare how many days they have gout symptoms. The goal is to see if early treatment can reduce pain and prevent the disease from getting worse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 128 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2023
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients with an attack of gout, diagnosed immediately or less than 5 days old. Gout is defined according to American-European criteria (Appendix 3). 2. Attack of gout affecting one (or more) peripheral joint (s) whatever (s) it (s): * Either a first crisis, * Either a new attack of a gout not treated with a hypo-uricemic or for which the hypo-uricemic treatment has not been taken for at least 6 months. 3. Uricemia ≥ 420 µmol / l, including under a diuretic (dosage carried out within 10 days before inclusion), 4. Age ≥ 18 years old, 5. Patient with a creatinine clearance ≥ 30 ml / min (dosage carried out within 10 days before inclusion), 6. Patient having read and understood the information letter and signed the consent form, 7. Affiliation to a social security scheme, 8. Woman of childbearing potential with effective contraception according to WHO definition (estrogen-progestins or intrauterine device or tubal ligation for more than 1 month and to be continued for at least 5 weeks after the last dose of the drug. ) and a negative urine pregnancy test on inclusion and throughout the duration of the study Where Postmenopausal woman: amenorrhea not medically induced for at least 12 months before the inclusion visit. Exclusion Criteria: 1. Patients under the age of 18, 2. Stop taking a hypouricemic agent for less than 6 months, 3. Known contraindication to ADENURIC 80 mg film-coated tablet: hypersensitivity to the active substance (febuxostat) or to one of the excipients, 4. Renal failure defined by creatinine clearance \<30 ml / min, 5. Hepatic disease defined by an increase to more than 2 times the normal of transaminases, alkaline phosphatases, to more than 3 times the normal of gamma-GT, 6. Non-weaned alcoholism, 7. Crisis more than 5 days old, 8. Patient who has received an organ or marrow transplant, 9. Person on Naproxen, mercaptopurine, azathioprine, Glycuronidation inhibitors and inducers, theophylline, macrolides, HMG Co-A reductase inhibitors and / or diuretic in combination with an ACE inhibitor or ARAII, 10. Person with rare hereditary disorders of galactose intolerance, lactase deficiency or glucose / galactose malabsorption 11. Poor understanding of the project due to neurological disease or lack of French practice, 12. Pregnant woman or likely to be in the absence of effective contraception (Women of childbearing age should have a negative urine pregnancy test), 13. Breastfeeding woman 14. Any history of pre-existing major cardiovascular disease (myocardial infarction, stroke, unstable angina, etc.), metabolic, endocrine, psychiatric or cancerous in uncontrolled development, 15. Person deprived of liberty by an administrative or judicial decision, 16. Person placed under judicial protection, guardianship or curatorship, 17. Participating patient who participated in the month preceding inclusion in another interventional drug trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gout are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
6 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHG Dieppe
RECRUITINGDieppe, France
-
CHI Elbeuf, Louvier, Val de Reuil
RECRUITINGElbeuf, France
-
CHU de Caen
RECRUITINGCaen, France
-
CHU de Rouen
RECRUITINGRouen, France
-
Centre Hospitalier Public du Cotentin
RECRUITINGCherbourg, France
-
GH Le Havre
RECRUITINGLe Havre, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Non-Interventional pilot study to explore the role of gut flora in disease
- Can a daily pill tame Gout's uric acid?
- Can a new drug combo crack Hard-to-Treat gout?
- Can a diabetes drug fight gout? metformin takes on febuxostat
- Can a weekly weight drug quiet gout attacks?
- Gout's crystal clues: could urate deposits flag hidden heart risk?